Vertex Pharma rises after rival genetic disorder drug setback
10/08/2026 15:00
BUZZ-Vertex Pharma rises after rival genetic disorder drug setback Updates
** Shares of drugmaker Vertex Pharmaceuticals VRTX.O climb 6.13% to $526.41
** Sionna Therapeutics SION.O says it will discontinue development of SION-719 experimental cystic fibrosis drug after it failed to meet main goal in a mid-stage trial
** Investors have been concerned Sionna can pose threat to VRTX's core cystic fibrosis business, but the trial failure is a clearing event - RBC Capital Markets
** VRTX markets Trikafta and Alyftrek for cystic fibrosis — a rare, chronic and life-shortening genetic disease which causes progressive lung damage
** Including session's moves, stock up ~17% YTD
(Reporting by Sriparna Roy in Bengaluru)
Recent news on Sionna Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial
Sionna hits record low after experimental drug misses mid-stage trial goal
Vertex Pharma rises after rival genetic disorder drug setback